# OnCo record paper-niche-2-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-niche-2-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-niche-2-nejm-2024" ;
  schema:name "NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients"@en ;
  schema:description "Two doses of immunotherapy over four weeks before surgery left little or no living tumour in 95% of patients with mismatch-repair-deficient colon cancer, and none had relapsed at three years."@en ;
  schema:url <https://onco.cc/key-papers/paper-niche-2-nejm-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2400634>, <https://clinicaltrials.gov/study/NCT03026140>, <https://pubmed.ncbi.nlm.nih.gov/?term=NICHE-2%20neoadjuvant%20nivolumab%20ipilimumab%20dMMR%20colon%20cancer%20Chalabi%20NEJM%202024> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2400634> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Chalabi M, Verschoor YL, Tan PB, et al." ;
  onco:related <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/roadmaps/colorectal-roadmap/>, <https://onco.cc/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/>, <https://onco.cc/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/>, <https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/>, <https://onco.cc/key-papers/paper-le-mmr-deficiency-science-2017/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/msi-mmr-testing/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/mmr/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:institutions <https://onco.cc/institutions/nki/> ;
  onco:pathways <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cancer-immunity-cycle/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/irae/> ;
  onco:trials <https://onco.cc/trials/niche-2/> ;
  onco:people <https://onco.cc/people/myriam-chalabi/>, <https://onco.cc/people/emile-voest/>, <https://onco.cc/people/ton-schumacher/>, <https://onco.cc/people/john-haanen/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-immunotherapy-response/>, <https://onco.cc/bottlenecks/b-surgery-radiation-innovation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/nejm/> .
